Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHF 6532 PK Linearity and Steady State in Healthy Subjects
NCT03942666Phase 1Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- May 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of timapiprant in asthma (6 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoints: Pharmacokinetic linearity of CHF 6532 at 48 hours and Steady state Pharmacokinetics of CHF 6532 at Day 10. Started May 2019; status: completed.
02
Drugs
timapiprant
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03942666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03942666.